FibroGen 
Welcome,         Profile    Billing    Logout  
 4 Products   45 Diseases  4 Products   53 Trials   1775 News 
74 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
pamrevlumab (FG-3019) / FibroGen
LELANTOS-1, NCT04371666 / 2020-000698-26: Phase 3 Trial of Pamrevlumab or Placebo With Systemic Corticosteroids in Participants With Non-ambulatory Duchenne Muscular Dystrophy (DMD)

Terminated
3
98
Europe, Canada, US, RoW
Pamrevlumab, FG-3019, Placebo, Corticosteroids
FibroGen
Duchenne Muscular Dystrophy
02/23
08/23
NCT03955146: Zephyrus I: Evaluation of Efficacy and Safety of Pamrevlumab in Participants With Idiopathic Pulmonary Fibrosis (IPF)

Apr 2023 - Sep 2023: Top-line data from ZEPHYRUS-1 trial for IPF
Terminated
3
393
US, RoW
Pamrevlumab, FG-3019, Placebo
FibroGen
Idiopathic Pulmonary Fibrosis
03/23
08/23
NCT04632940 / 2020-000699-39: Phase 3 Trial of Pamrevlumab or Placebo in Combination With Systemic Corticosteroids in Participants With Ambulatory DMD

Hourglass Jan 2023 - Jun 2023 : From P3 trial for duchenne muscular dystrophy
Terminated
3
73
Europe, Canada, US, RoW
Pamrevlumab, FG-3019, Placebo, Corticosteroids
FibroGen, FibroGen, Inc.
Duchenne Muscular Dystrophy
06/23
12/23
FGCL-3019-095, NCT04419558 / 2020-000697-22: Zephyrus II: Efficacy and Safety Study of Pamrevlumab in Participants With Idiopathic Pulmonary Fibrosis (IPF)

Apr 2024 - Sep 2024: Topline data from ZEPHYRUS-2 trial for IPF
Terminated
3
372
Europe, US, RoW
Pamrevlumab, FG-3019, Placebo
FibroGen
Idiopathic Pulmonary Fibrosis
09/23
09/23
LAPIS, NCT03941093 / 2019-001925-28: Evaluation of Efficacy and Safety of Neoadjuvant Treatment With Pamrevlumab in Combination With Chemotherapy (Either Gemcitabine Plus Nab-paclitaxel or FOLFIRINOX) in Participants With Locally Advanced, Unresectable Pancreatic Cancer

Completed
3
284
Europe, Canada, US, RoW
Pamrevlumab + Gemcitabine + Nab-paclitaxel or Pamrevlumab + FOLFIRINOX, FG-3019, Gemzar, Abraxane, Eloxitan, Leucovorin, Camptosar, 5-Fluracil, Efudex, Placebo + Gemcitabine + Nab-paclitaxel or Placebo + FOLFIRINOX
FibroGen
Pancreatic Cancer Non-resectable
06/24
06/24
Precision Promise, NCT04229004: A Multi-center Trial to Evaluate Multiple Regimens in Metastatic Pancreatic Cancer

Completed
3
502
US
Gemcitabine combined with nab-paclitaxel, Dose -mFOLFIRINOX, Dose - Pamrevlumab combined with gemcitabine and nab-paclitaxel, Dose- Canakinumab and Spartalizumab combined with nab-paclitaxel and gemcitabine, Drug: Dose -SM-88
Pancreatic Cancer Action Network
Metastatic Pancreatic Cancer, Metastatic Pancreatic Adenocarcinoma
02/25
02/25
MISSION, NCT02606136 / 2023-000321-80: Trial of Pamrevlumab (FG-3019), in Non-Ambulatory Participants With Duchenne Muscular Dystrophy (DMD)

Terminated
2
21
US
Pamrevlumab, Monoclonal Antibody to Connective tissue growth factor (CTGF), FG-3019
FibroGen, FibroGen, Inc.
Duchenne Muscular Dystrophy
05/20
08/23
2020-001472-14: Efficacy of pamrevlumab, a connective tissue growth factor monoclonal antibody, in patients with SARS-COV-2 infection.

Not yet recruiting
2
68
Europe
Pamrevlumab, FG-3019, Infusion
Istituto Nazionale per le Malattie Infettive “Lazzaro Spallanzani”, FibroGen, Inc.
Patients with documented SARS-CoV-2 infection, Patients with documented SARS-CoV-2 infection, Diseases [C] - Respiratory Tract Diseases [C08]
 
 
Evrenzo (roxadustat) / FibroGen
ChiCTR2000035054: An observational study on roxadustat in the treatment of renal anemia in peritoneal dialysis patients

Recruiting
4
150
 
take Roxadustat capsule ;Recombinant human erythropoietin
the Second Affiliated Hospital of Harbin Medical University; The Second Affiliated Hospital of Harbin Medical University, self - financing
Peritoneal Dialysis
 
 
ChiCTR1900028462: Roxadustat Treatment for Chronic Erythropoietin-Hyporesponsive Anemia in Subjects Undergoing Long-Term Hemodialysis: a Single-Arm, Multicenter Study

Completed
4
50
 
Roxadustat
Shandong Provincial Hospital; Shandong Provincial Hospital, self-raised
chronic kidney disease undergoing long-term hemodialysis
 
 
ChiCTR2100044616: Efficacy of roxadustat for diabetic nephropathy anemia patients in different stages of CKD and its effect on factors associated with renal fibrosis

Recruiting
4
40
 
roxadustat
Suqian People's Hospital of Nanjing Drum Tower Hospital Group; Suqian People's Hospital?of?Nanjing Drum Tower Hospital Group, Social Development of Science and Technology Projects in Suqian City (No. S201907). And funded by Science and Technology Information Network in Suqian City (No. Z2019162).
anemia patients in different stages of chronic kidney diseases
 
 
ChiCTR2000041202: A multicenter, randomized, controlled trial to evaluate the effects of Roxadustat on left ventricular hypertrophy and cardiac function in hemodialysis patients

Recruiting
4
100
 
Roxadustat ;Erythropoietin
The Third Affiliated Hospital of Chongqing Medical University (Gener Hospital); The Third Affiliated Hospital of Chongqing Medical University, Self-funded
CKD5
 
 
ChiCTR1900026596: Efficacy and safety of rosastatin capsules in hemodialysis patients with erythropoietin resistance

Recruiting
4
40
 
Oral rostastat capsule ;Recombinant human erythropoietin
The First Affiliated Hospital of Chengdu Medical College; The First Affiliated Hospital of Chengdu Medical College, Self-financing
Hemodialysis combined with anemia
 
 
ChiCTR1900026597: Effect of Roxadustat on residual renal function in Peritoneal Dialysis patients

Recruiting
4
60
 
take Roxadustat capsule ;Recombinant human erythropoietin and iron
The First Affiliated Hospital of Chengdu Medical College; The First Affiliated Hospital of Chengdu Medical College, self - financing
Peritoneal Dialysis
 
 
ChiCTR2000039934: The role of oral losartan in the prevention of acute mountain sickness: a randomized controlled trial

Not yet recruiting
4
200
 
oral Roxadustat capsules 50mg, BIW ;Oral placebo capsules,the same dosage as Oral Roxadustat
Western Theater Air Force Hospital; Western Theater Air Force Hospital, Western Theater Air Force Hospital
Acute altitude illness
 
 
ChiCTR2000030960: Explore the protective effect of Roxadustat on grafts in organ transplants

Not yet recruiting
4
214
 
oral Roxadustat ;conventional therapy
The Third Affiliated Hospital of Sun Yat-Sen University; The Third Affiliated Hospital of Sun Yat-Sen University, the National Natural Science Foundation of China
end-stage renal disease
 
 
ChiCTR2000032858: A prospective study of roxadustat in reducing delayed graft function and acute rejection after renal transplantation

Recruiting
4
238
 
Roxadustat and conventional treatment ;conventional treatment
The Third Affiliated Hospital，Sun Yat-Sen University; The Third Affiliated Hospital of Zhongshan University, Researchers spontaneous
delayed graft function after kidney transplantation
 
 
ChiCTR2200057232: Clinical study of roxadustat in the treatment of diabetic nephropathy anemia

Not yet recruiting
4
80
 
;
Affiliated Hospital of Xuzhou Medical University; Affiliated Hospital of Xuzhou Medical University, Research group
Diabetic Nephropathy
 
 
ChiCTR2200057231: Effect of roxadustat on iron metabolism in peritoneal dialysis patients

Recruiting
4
128
 
no intervention ;no intervention
Affiliated Hospital of Xuzhou Medical University; Affiliated Hospital of Xuzhou Medical University, Jiangsu Graduate Research and Practice Innovation Program
chronic kidney disease
 
 
NCT05691257: Study of the Safety and Efficacy of Roxadustat in the Treatment of Heart Failure With Chronic Kidney Disease and Anemia

Not yet recruiting
4
300
NA
Roxadustat, Recombinant human eythropoietin and/or Iron agents
China-Japan Friendship Hospital
Heart Failure, Chronic Kidney Diseases, Anemia
08/23
12/23
ChiCTR2000030998: Evaluation of efficacy and safety of Roxadustat in the treatment of anemia in patients with chronic kidney disease receiving hemodialysis or peritoneal dialysis: a real-world registration study in China

Not yet recruiting
4
200
 
Roxadustat
West China Hospital, Sichuan University; West China Hospital, Sichuan University, 1.3.5 project for disciplines of excellence, West China Hospital, Sichuan University
anemia in patients with chronic kidney disease receiving hemodialysis or peritoneal dialysis
 
 
NCT06115421: Effect of Low Doses of Hypoxia-inducible Factor- Prolyl Hydroxylase Enzyme Inhibitor Plus Iron in the Treatment of Anemia in Dialysis-dependent Chronic Kidney Disease Patients

Recruiting
4
72
RoW
Roxadustat, hypoxia-inducible factor- prolyl hydroxylase enzyme inhibitor
Alexandria University
Anemia in Dialysis-dependent CKD Patients
03/24
05/24
ChiCTR2100046322: A National, Multi-Center, Prospective Registry Study to Evaluate the Long-Term Safety and effectiveness of Roxadustat for Treatment of Anemia in Subjects with Chronic Kidney Disease (ROXSTAR Registry)

Completed
4
2000
 
Nil
The First Affiliated Hospital, Zhejiang University School of Medicine; FibroGen (China) Medical Technology Development Company Limited, FibroGen (China) Medical Technology Development Co., Ltd.
CKD anemia
 
 
Effectiveness and safety of roxadustat in Chinese patients with anemia of CKD receiving PD, ChiCTR2100044799: NANLING: An Open-Label Single Arm, Multicenter, Phase IV Study of the Effectiveness and Safety of Roxadustat in Chinese Patients with Anemia of ChronicKidney Disease (CKD) Receiving Peritoneal Dialysis (PD)

Completed
4
200
 
Roxadustat Treatment
Guangdong Provincial People's Hospital; Guangdong Provincial People's Hospital, FibroGen (China) Medical Technology Development Co., Ltd.
Renal Anemia
 
 
ChiCTR2100044135: a Multicentre real world study and pharmacoeconomic analysis of Roxadustat in the treatment of anemia in CKD

Recruiting
4
300
 
Roxadustat
Shenzhen People's Hospital; Level of the institution：, Shenzhen Key Laboratory of Kidney Diseases, Shenzhen People's Hospital
anemia in patients with chronic kidney disease receiving or not-receiving dialysis
 
 
ChiCTR2100045359: A Randomized, Control, Open-Label, Multi-center Study Evaluating the Efficacy and Safety of Roxadustat at Lower Starting Dose for the Treatment of Anemia in Subjects with Chronic Kidney Disease Not on Dialysis

Completed
4
250
 
1-step lower weight-based starting dose group: < 60 kg: 50 mg TIW, >= 60 kg: 70 mg TIW ;Control arm: standard weight-based starting dose group: < 60 kg: 70 mg TIW, >= 60 kg: 100 mg TIW
Chinese PLA General Hospital; Chinese PLA General Hospital, FibroGen (China) Medical Technology Development Company Limited
Chronic Kidney Disease
 
 
ChiCTR2300068533: Roxadustat for Anemia in Patients Receiving Maintenance Hemodialysis: A Single-center, Open-label, Randomized, Controlled Study

Recruiting
4
56
 
Roxadustat (Airuizhuo) ;Yibiao
Shanghai Ninth People’s Hospital, Shanghai Jiao Tong University School of Medicine; Shanghai Ninth People’s Hospital, Shanghai Jiao Tong University School of Medicine, self-financing
Anemia in CKD
 
 
ChiCTR2200061138: Efficacy and safety of roxadustat in delaying the progression of chronic kidney disease: a two-way, single center, cohort study

Not yet recruiting
4
66
 
Roxadustat capsule
Department of Nephrology, DaPing Hospital of Army Medical University, ChongQing, China; Department of Nephrology, DaPing Hospital of Army Medical University, Chongqing technological innovation and application demonstration (social and people's livelihood) general project
Chongqing technological innovation and application demonstration (social and people's livelihood) general project
 
 
ChiCTR2100047094: Effect of roxastat on anemia and vascular calcification in non-dialysis DKD patients with microinflammation

Recruiting
4
130
 
Roxadustat ;ESA
Pudong Hospital affiliated to Fudan University; Pudong Hospital affiliated to Fudan University, Research Fund
DKD
 
 
ChiCTR2300071087: Efficacy of Roxadustat on Anemia in CKD

Not yet recruiting
4
140
 
No ;No
The Second Affiliated Hospital of Shantou University Medical College; The Second Affiliated Hospital of Shantou University Medical College, N/A
chronic kidney disease
 
 
NCT06006949: Roxadustat Combined With Luspatercept Versus Luspatercept Monotherapy in the Treatment of Refractory MDS-RS

Not yet recruiting
4
62
RoW
Roxadustat, Luspatercept
Peking Union Medical College Hospital
Myelodysplastic Syndromes
08/24
08/25
REACH-ROAD, ChiCTR1900025765: Renal disEAse observational CoHort Database-ROxadustat in treating Anemia in Dialysis patients

Not yet recruiting
4
2000
 
N/A
Sichuan Provincial People's Hospital; Sichuan Provincial People's Hospital, self-funding
Chronic Kidney Disease
 
 
ChiCTR2100054190: Study of thyroid function status in patients with renal anemia before and after roxadustat or erythropoietin treatment

Recruiting
4
160
 
No ;No
Shenzhen Second People's Hospital, the First Affiliated Hospital of Shenzhen University; Shenzhen Second People's Hospital, the First Affiliated Hospital of Shenzhen University, None
Renal anemia and thryoid diseases
 
 
PANGU-stepup, NCT07045155: Pegmolesatide Treatment for Anemia in Patients Undergoing Long-term Dialysis

Not yet recruiting
4
240
RoW
The rHuEPO Monotherapy Group (Control Group), Control Group, The Pegmolesatide and Roxadustat Combination Therapy Group (Exploratory Group), Exploratory Group, The Pegmolesatide Monotherapy Group (Experimental group), Experimental group
Chinese PLA General Hospital, Jiangsu Hansoh Pharmaceutical Co., Ltd.
Dialysis; Complications, Chronic Kidney Disease 5D, Renal Anemia of Chronic Kidney Disease, Renal Anaemia, Renal Anemia, Chronic
12/27
12/28
ChiCTR2500100313: Evaluation of the efficacy of Roxadustat combined with oral iron in the treatment of renal anemia in hemodialysis patients who meet iron standards: a randomized controlled clinical study

Not yet recruiting
4
48
 
Roxadustat combined with oral iron supplements; Roxadustat
Ya'an People's Hospital; Ya'an People's Hospital, Project of Sichuan Geriatric Clinical Research Center
chronic kidney disease
 
 
NCT04925011: Investigating the Efficacy and Safety of Roxadustat (FG-4592) for Treatment of Anemia in Pediatric Patients With CKD

Recruiting
3
30
RoW
Roxadustat
Mao Jianhua
Anemia Associated With Chronic Kidney Disease
06/22
12/22
MATTERHORN, NCT03263091 / 2017-001773-17: Efficacy and Safety of Roxadustat for Treatment of Anemia in Participants With Lower Risk Myelodysplastic Syndrome With Low Red Blood Cell Transfusion Burden

Hourglass Jan 2023 - Dec 2023 : Data from trial for anemia in patients with MDS
Checkmark Data from trial for anemia in patients with MDS
Dec 2019 - Dec 2019: Data from trial for anemia in patients with MDS
Terminated
3
184
Europe, Canada, US, RoW
Roxadustat, FG-4592, ASP1517, AZD9941, Placebo
FibroGen, AstraZeneca, Astellas Pharma Inc
Primary MDS (Very Low, Low or Intermediate IPSS-R With <5% Blasts), Anemia
03/23
06/23
FGCL-4592-898, NCT05301517: A Study to Evaluate the Efficacy and Safety of Roxadustat for the Treatment of Anemia in Participants Receiving Chemotherapy Treatment for Non-Myeloid Malignancies

Completed
3
159
RoW
SEPO®, Recombinant human erythropoietin-α [rHuEPO-α], Roxadustat, FG-4592
FibroGen
Chemotherapy Induced Anemia
04/23
04/23
PRELIFS, NCT06772272: Effect of Perioperative Roxadustat in Elective Lumbar Interbody Fusion Surgery.

Active, not recruiting
3
158
RoW
Roxadustat, FG-4592, Evrenzo
Second Affiliated Hospital, School of Medicine, Zhejiang University
Perioperative Anemia
11/26
05/27
NCT05970172: A Study of Roxadustat to Treat Anemia in Children and Teenagers With Chronic Kidney Disease

Recruiting
3
100
Europe, RoW
Roxadustat, ASP1517, FG-4592, Evrenzo
Astellas Pharma Global Development, Inc.
Chronic Kidney Disease, Renal Anemia
11/25
09/26
NCT03303066: Efficacy and Safety of FG-4592 for Treatment of Anemia in Participants With Lower Risk Myelodysplastic Syndrome (MDS)

Hourglass Jan 2023 - Dec 2023 : Data from trial for anemia in patients with low risk MDS
Completed
2/3
43
RoW
FG-4592, Roxadustat, AZD9941, Placebo
FibroGen, AstraZeneca
Anemia, Myelodysplastic Syndrome
01/23
02/23
ACTRN12625000491460: A study of the short-term effects of oral Roxadustat in volunteers over the age of 40.

Not yet recruiting
2
10
 
Royal Perth Hospital, National Health and Medical Research Council
Postoperative Complications, Surgical Site Infection
 
 
ACTRN12624000188538: A pilot study of preoperative Roxadustat in patients undergoing major surgery.

Recruiting
2
150
 
Royal Perth Hospital, National Health and Medical Research Council
Postoperative Complications, Surgical site infection
 
 
ROXAMI, NCT04803864: Study of Roxadustat in the Treatment of Acute Myocardial Infarction

Recruiting
2
158
RoW
Roxadustat, Evrenzo
Ruijin Hospital
ST Elevation Myocardial Infarction
09/22
08/23
NCT05010460: Study of Roxadustat for Reducing the Incidence of Acute Kidney Injury After Coronary Artery Bypass Grafting

Recruiting
2
318
RoW
Roxadustat, Evrenzo, Placebo
Peking Union Medical College Hospital, Beijing Hospital
Coronary Artery Bypass
08/23
10/23
FOXTROT, NCT05810311: The Effect of Roxadustat on Renal Oxygenation in Diabetes Nephropathy

Not yet recruiting
2
30
Europe
Roxadustat, Evrenzo, Darbepoietin Alfa, Aranesp
Region Stockholm
Diabetes Complications, Diabetes; Nephropathy (Manifestation)
01/27
12/27
ROXA-HD-MIA, NCT06903559: Roxadustat's Effect on Heart, Nutrition, and Inflammation in Hemodialysis Patients

Recruiting
1/2
46
RoW
Roxadustat, Evernzo, Conventional Anemia Management, Erythropoiesis-Stimulating Agent, Iron Supplementation
Mansoura University
Kidney Failure, Chronic, Malnutrition-Inflammation Syndrome, Anemia in End Stage Renal Disease, Cardiovascular Diseases (CVD)
10/25
11/25
ROXA-BN-HD, NCT06917950: Roxadustat for Bone and Neuropsychiatric Aspects in Hemodialysis Patients

Recruiting
1/2
46
RoW
Roxadustat, Conventional Anemia Management
Mansoura University
Kidney Failure,Chronic, Anemia in End Stage Renal Disease, Depression Anxiety Disorder
10/25
11/25
NCT06020833: A Single-arm Trial of Roxadustat Combined With Retinoic Acid in the Treatment of Refractory Low-risk MDS

Not yet recruiting
1/2
25
NA
Roxadustat in combination with retinoic acid
Peking Union Medical College Hospital
Myelodysplastic Syndromes
10/25
12/26
HEC53856-RAD-102, NCT04925661: HEC53856 Phase Ib Study in Patients With Non-dialysis Renal Anemia

Completed
1
40
RoW
HEC53856, Roxadustat, Placebo
Sunshine Lake Pharma Co., Ltd., Nicoya Therapeutics (Shanghai) Co., Ltd.
Chronic Kidney Diseases, Renal Anemia
08/23
08/23
ChiCTR2200058594: A randomized controlled study of Rosallistat in the treatment of anemia in patients with multiple myeloma renal insufficiency

Recruiting
1
86
 
Roxadustat ;None
The First Affiliated Hospital of Zhejiang University School of Medicine; The First Affiliated Hospital of Zhejiang University School of Medicine, none
Multiple Myeloma
 
 
ChiCTR2000039194: Clinical application of hypoxia inducible factor proline hydroxylase inhibitor in restless legs syndrome of end stage renal disease

Recruiting
N/A
240
 
Roxadustat ;Oral neurotropin ;Neurotropin injection ;HDF
The Sencond Hospital of Tianjin medical university; The Sencond Hospital of Tianjin medical university, Self financing
restless legs syndrome
 
 
ChiCTR2100048276: Safety assessment of roxadustat in the treatment of renal anemia in dialysis patients: a retrospective study based on the ''Ruixiang Xinsheng'' patient assistance program

Not yet recruiting
N/A
8000
 
Null
Beijing University First Hospital; Beijing University First Hospital, FibroGen (China) Medical Technology Development Co., Ltd.
Renal Anemia
 
 
ChiCTR2100044086: Effect of Roxadustat on Erythrocyte Life Span in Long-term Hemodialysis Patients with Renal Anemia

Completed
N/A
27
 
Roxadustat
Shandong Provincial Hospital; Shandong Provincial Hospital, Special Fund for Renal Anemia
Maintenance Hemodialysis with Renal Anemia
 
 
ChiCTR2000031222: Cancelled by the investigator A prospective randomized controlled trial of roxadustat for the first recipient to alleviate delayed graft function and acute rejection after renal transplantation

Suspended
N/A
238
 
Roxadustat Capsules and routine treatment ;routine treatment
The Third Affiliated Hospital of Sun Yat-Sen University; The Third Affiliated Hospital, Sun Yat-Sen University, Researchers spontaneous
Delayed graft function after renal transplantation
 
 
NCT05053893: Roxadustat Combined With Sacubitril Valsartan Sodium Tablets in the Treatment of Cardiorenal Anemia Syndrome

Recruiting
N/A
40
RoW
Roxadustat;Sacubitril Valsartan Sodium Tablets;, Entresto®, EPO; ACEI / ARB
The Affiliated Hospital of Qingdao University
Cardio-Renal Syndrome
07/22
09/22
ChiCTR2000036633: The effect of roxadustat on infarct size reduction of acute myocardial infarction: a randomized controlled trial

Not yet recruiting
N/A
158
 
Roxadustat 100mg, three times a week, for 2 weeks; Standard treatment. ;Standard treatment
Ruijin Hospital affiliated to Shanghai Jiaotong University School of Medicine; Ruijin Hospital affiliated to Shanghai Jiaotong University School of Medicine, Shanghai shenkang hospital development center
Acute Myocardial Infarction
 
 
ChiCTR2100048566: Effect of oral roxadustat on renal anemia after allogeneic kidney transplantation: an observational study

Not yet recruiting
N/A
152
 
None
Renji Hospital affiliated to Shanghai Jiao Tong University Medical College; Renji Hospital affiliated to Shanghai Jiao Tong University Medical College, None
Kidney transplant
 
 
ChiCTR2200065159: Efficacy of roxadustat in patients with renal anemia associated with inflammatory status

Recruiting
N/A
100
 
None
Zhongda Hospital Affiliated to Southeast University; Zhongda Hospital Affiliated to Southeast University, Self financing
Renal anemia
 
 
ChiCTR2100050031: A practical randomized controlled trial of hypoxia inducible factor prolyl hydroxylase inhibitor in the treatment of cardio-renal-anemia syndrome

Not yet recruiting
N/A
60
 
Roxadustat capsule ;recombinant human erythropoietin
Beijing Hepingli Hospital; Beijing Hepingli Hospital, Dongcheng District Health Technology Program
cardio-renal-anemia syndrome
 
 
NCT04502537: Roxadustat for Anemia in Patients With CKD

Recruiting
N/A
200
RoW
Roxadustat, Roxadustat capsules, erythropoietin, Recombinant Human Erythropoietin Injection(CHO cell)
Shenzhen Second People's Hospital
Anemia of Chronic Kidney Disease
06/23
09/23
ChiCTR2300076409: Effect of roxadustat in peritoneal dialysis patients with erythropoietin hyporesponsiveness: A real-world 16-week study

Completed
N/A
152
 
N/A; N/A
The Second Affiliated Hospital of Xuzhou Medical University; The Second Affiliated Hospital of Xuzhou Medical University, Self-financed
Peritoneal dialysis
 
 
ChiCTR2400086902: Efficacy of roxadustat versus ESAs in peritoneal dialysis patients during the COVID-19 pandemic: A retrospective study

Completed
N/A
154
 
N/A; N/A
The Second Affiliated Hospital of Xuzhou Medical University; The Second Affiliated Hospital of Xuzhou Medical University, Self-financing
Peritoneal dialysis
 
 
ChiCTR2200065296: A multicenter clinical study of roxadustat to improve outcomes in peritoneal dialysis patients

Not yet recruiting
N/A
100
 
none
Shanghai East hospital (East Hospital Affiliated to Tongji University); Shanghai East Hospital (East Hospital Affiliated to Tongji University), Shanghai East Hospital,
end stage renal disease
 
 
ChiCTR2300070478: Clinical cohort study of the effect of hypoxia-inducible factor prolyl hydroxylase inhibitor (roxadustat) on cognitive function in maintenance hemodialysis patients

Recruiting
N/A
100
 
NA ;NA
Deyang People's Hospital; Deyang People's Hospital, Self-funded
Chronic kidney disease
 
 
ChiCTR2200057485: The study of efficacy and safety of Roxadustat in anemia patients after kidney transplantation

Not yet recruiting
N/A
160
 
Roxadustat ;Recombinant human erythropoietin
West China Hospital, Sichuan University; West China Hospital, Sichuan University, Supported by 1.3.5 Project No.ZYJC18004
kindey transplant
 
 
ChiCTR2500097135: Effect of Roxadustat treatment on patients with diabetes mellitus combined with chronic kidney disease

Not yet recruiting
N/A
500
 
NA; NA; NA
Shanghai General Hospital; Shanghai General Hospital, Self selected topic
non dialysis type 2 diabetes patients with chronic kidney disease
 
 
NCT04408820: Post-marketing Surveillance of EVRENZO® Tablets (Roxadustat) in Patients With Renal Anemia

Active, not recruiting
N/A
2104
Japan
Roxadustat, ASP1517, Evrenzo
Astellas Pharma Inc
Renal Anemia
06/25
06/25
ChiCTR2500096786: An Observational Study on the Increased Synthesis of Fetal Hemoglobin Induced by Roxadustat in Patients with Renal Anemia

Recruiting
N/A
100
 
None; None
Army Military Medical University Second Affiliated Hospital; Army Military Medical University Second Affiliated Hospital, Chongqing Municipal Education Commission Science and Technology Research Program Major Project, KJZD-M202312802, Study on the Role and Mechanism of Heterogeneity of Hematopoietic Stem Cell Function in the Efficacy of Hematopoietic Stem Cell Transplantation
Chronic kidney disease
 
 
Roxa-NDD-CKD Anemia Study, ChiCTR2500097406: A multicenter, prospective study on the efficacy and safety of roxadustat (Bereisheng®) in the treatment of renal anemia in non-dialysis patients with chronic kidney disease

Not yet recruiting
N/A
50
 
Roxadustat Capsules
The First Affiliated Hospital of Jinan University; Chengdu Brilliant Pharmaceutical Co., Ltd., Chengdu Brilliant Pharmaceutical Co., Ltd.
Renal anemia in non-dialysis patients with chronic kidney disease
 
 
ChiCTR2200061848: A single-center prospective observational cohort study on the effect of different therapeutic strategies on cardiovascular prognosis of patients with end-stage renal disease complicated with renal anemia

Not yet recruiting
N/A
360
 
Erythropoietin ;Roxadustat ;Roxadustat
The Second Hospital of Tianjin Medical University; The Second Hospital of Tianjin Medical University, self-raised
Chronic Kidney Disease
 
 
FG-3246 / Fortis Therap, FibroGen
NCT06842498: A Study of FG-3246 in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Not yet recruiting
2
75
US
FG-3246, FOR46
FibroGen
Metastatic Castration-Resistant Prostate Cancer
09/27
09/27
NCT05011188: FOR46 in Combination With Enzalutamide in Patients With Metastatic Castration Resistant Prostate Cancer

Recruiting
1/2
41
US
FOR46, Antibody-Drug Conjugate (ADC), anti-CD46 antibody conjugate, Enzalutamide, XTANDI, Pegfilgrastim, G-CSF, Blood Samples, Blood Specimen, Biospecimen
Rahul Aggarwal, Fortis Therapeutics, Inc., FibroGen
Metastatic Castration-resistant Prostate Cancer, Prostate Cancer
04/27
04/27
NCT03575819: A Phase 1 Study of FOR46 in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Completed
1
56
US
FOR46
Fortis Therapeutics, Inc.
Prostate Cancer Metastatic
11/23
11/23
FG-3165 / FibroGen
No trials found
HFB200901 / HiFiBiO, FibroGen
No trials found
HFB101110 / FibroGen
No trials found
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
pamrevlumab (FG-3019) / FibroGen
LELANTOS-1, NCT04371666 / 2020-000698-26: Phase 3 Trial of Pamrevlumab or Placebo With Systemic Corticosteroids in Participants With Non-ambulatory Duchenne Muscular Dystrophy (DMD)

Terminated
3
98
Europe, Canada, US, RoW
Pamrevlumab, FG-3019, Placebo, Corticosteroids
FibroGen
Duchenne Muscular Dystrophy
02/23
08/23
NCT03955146: Zephyrus I: Evaluation of Efficacy and Safety of Pamrevlumab in Participants With Idiopathic Pulmonary Fibrosis (IPF)

Apr 2023 - Sep 2023: Top-line data from ZEPHYRUS-1 trial for IPF
Terminated
3
393
US, RoW
Pamrevlumab, FG-3019, Placebo
FibroGen
Idiopathic Pulmonary Fibrosis
03/23
08/23
NCT04632940 / 2020-000699-39: Phase 3 Trial of Pamrevlumab or Placebo in Combination With Systemic Corticosteroids in Participants With Ambulatory DMD

Hourglass Jan 2023 - Jun 2023 : From P3 trial for duchenne muscular dystrophy
Terminated
3
73
Europe, Canada, US, RoW
Pamrevlumab, FG-3019, Placebo, Corticosteroids
FibroGen, FibroGen, Inc.
Duchenne Muscular Dystrophy
06/23
12/23
FGCL-3019-095, NCT04419558 / 2020-000697-22: Zephyrus II: Efficacy and Safety Study of Pamrevlumab in Participants With Idiopathic Pulmonary Fibrosis (IPF)

Apr 2024 - Sep 2024: Topline data from ZEPHYRUS-2 trial for IPF
Terminated
3
372
Europe, US, RoW
Pamrevlumab, FG-3019, Placebo
FibroGen
Idiopathic Pulmonary Fibrosis
09/23
09/23
LAPIS, NCT03941093 / 2019-001925-28: Evaluation of Efficacy and Safety of Neoadjuvant Treatment With Pamrevlumab in Combination With Chemotherapy (Either Gemcitabine Plus Nab-paclitaxel or FOLFIRINOX) in Participants With Locally Advanced, Unresectable Pancreatic Cancer

Completed
3
284
Europe, Canada, US, RoW
Pamrevlumab + Gemcitabine + Nab-paclitaxel or Pamrevlumab + FOLFIRINOX, FG-3019, Gemzar, Abraxane, Eloxitan, Leucovorin, Camptosar, 5-Fluracil, Efudex, Placebo + Gemcitabine + Nab-paclitaxel or Placebo + FOLFIRINOX
FibroGen
Pancreatic Cancer Non-resectable
06/24
06/24
Precision Promise, NCT04229004: A Multi-center Trial to Evaluate Multiple Regimens in Metastatic Pancreatic Cancer

Completed
3
502
US
Gemcitabine combined with nab-paclitaxel, Dose -mFOLFIRINOX, Dose - Pamrevlumab combined with gemcitabine and nab-paclitaxel, Dose- Canakinumab and Spartalizumab combined with nab-paclitaxel and gemcitabine, Drug: Dose -SM-88
Pancreatic Cancer Action Network
Metastatic Pancreatic Cancer, Metastatic Pancreatic Adenocarcinoma
02/25
02/25
MISSION, NCT02606136 / 2023-000321-80: Trial of Pamrevlumab (FG-3019), in Non-Ambulatory Participants With Duchenne Muscular Dystrophy (DMD)

Terminated
2
21
US
Pamrevlumab, Monoclonal Antibody to Connective tissue growth factor (CTGF), FG-3019
FibroGen, FibroGen, Inc.
Duchenne Muscular Dystrophy
05/20
08/23
2020-001472-14: Efficacy of pamrevlumab, a connective tissue growth factor monoclonal antibody, in patients with SARS-COV-2 infection.

Not yet recruiting
2
68
Europe
Pamrevlumab, FG-3019, Infusion
Istituto Nazionale per le Malattie Infettive “Lazzaro Spallanzani”, FibroGen, Inc.
Patients with documented SARS-CoV-2 infection, Patients with documented SARS-CoV-2 infection, Diseases [C] - Respiratory Tract Diseases [C08]
 
 
Evrenzo (roxadustat) / FibroGen
ChiCTR2000035054: An observational study on roxadustat in the treatment of renal anemia in peritoneal dialysis patients

Recruiting
4
150
 
take Roxadustat capsule ;Recombinant human erythropoietin
the Second Affiliated Hospital of Harbin Medical University; The Second Affiliated Hospital of Harbin Medical University, self - financing
Peritoneal Dialysis
 
 
ChiCTR1900028462: Roxadustat Treatment for Chronic Erythropoietin-Hyporesponsive Anemia in Subjects Undergoing Long-Term Hemodialysis: a Single-Arm, Multicenter Study

Completed
4
50
 
Roxadustat
Shandong Provincial Hospital; Shandong Provincial Hospital, self-raised
chronic kidney disease undergoing long-term hemodialysis
 
 
ChiCTR2100044616: Efficacy of roxadustat for diabetic nephropathy anemia patients in different stages of CKD and its effect on factors associated with renal fibrosis

Recruiting
4
40
 
roxadustat
Suqian People's Hospital of Nanjing Drum Tower Hospital Group; Suqian People's Hospital?of?Nanjing Drum Tower Hospital Group, Social Development of Science and Technology Projects in Suqian City (No. S201907). And funded by Science and Technology Information Network in Suqian City (No. Z2019162).
anemia patients in different stages of chronic kidney diseases
 
 
ChiCTR2000041202: A multicenter, randomized, controlled trial to evaluate the effects of Roxadustat on left ventricular hypertrophy and cardiac function in hemodialysis patients

Recruiting
4
100
 
Roxadustat ;Erythropoietin
The Third Affiliated Hospital of Chongqing Medical University (Gener Hospital); The Third Affiliated Hospital of Chongqing Medical University, Self-funded
CKD5
 
 
ChiCTR1900026596: Efficacy and safety of rosastatin capsules in hemodialysis patients with erythropoietin resistance

Recruiting
4
40
 
Oral rostastat capsule ;Recombinant human erythropoietin
The First Affiliated Hospital of Chengdu Medical College; The First Affiliated Hospital of Chengdu Medical College, Self-financing
Hemodialysis combined with anemia
 
 
ChiCTR1900026597: Effect of Roxadustat on residual renal function in Peritoneal Dialysis patients

Recruiting
4
60
 
take Roxadustat capsule ;Recombinant human erythropoietin and iron
The First Affiliated Hospital of Chengdu Medical College; The First Affiliated Hospital of Chengdu Medical College, self - financing
Peritoneal Dialysis
 
 
ChiCTR2000039934: The role of oral losartan in the prevention of acute mountain sickness: a randomized controlled trial

Not yet recruiting
4
200
 
oral Roxadustat capsules 50mg, BIW ;Oral placebo capsules,the same dosage as Oral Roxadustat
Western Theater Air Force Hospital; Western Theater Air Force Hospital, Western Theater Air Force Hospital
Acute altitude illness
 
 
ChiCTR2000030960: Explore the protective effect of Roxadustat on grafts in organ transplants

Not yet recruiting
4
214
 
oral Roxadustat ;conventional therapy
The Third Affiliated Hospital of Sun Yat-Sen University; The Third Affiliated Hospital of Sun Yat-Sen University, the National Natural Science Foundation of China
end-stage renal disease
 
 
ChiCTR2000032858: A prospective study of roxadustat in reducing delayed graft function and acute rejection after renal transplantation

Recruiting
4
238
 
Roxadustat and conventional treatment ;conventional treatment
The Third Affiliated Hospital，Sun Yat-Sen University; The Third Affiliated Hospital of Zhongshan University, Researchers spontaneous
delayed graft function after kidney transplantation
 
 
ChiCTR2200057232: Clinical study of roxadustat in the treatment of diabetic nephropathy anemia

Not yet recruiting
4
80
 
;
Affiliated Hospital of Xuzhou Medical University; Affiliated Hospital of Xuzhou Medical University, Research group
Diabetic Nephropathy
 
 
ChiCTR2200057231: Effect of roxadustat on iron metabolism in peritoneal dialysis patients

Recruiting
4
128
 
no intervention ;no intervention
Affiliated Hospital of Xuzhou Medical University; Affiliated Hospital of Xuzhou Medical University, Jiangsu Graduate Research and Practice Innovation Program
chronic kidney disease
 
 
NCT05691257: Study of the Safety and Efficacy of Roxadustat in the Treatment of Heart Failure With Chronic Kidney Disease and Anemia

Not yet recruiting
4
300
NA
Roxadustat, Recombinant human eythropoietin and/or Iron agents
China-Japan Friendship Hospital
Heart Failure, Chronic Kidney Diseases, Anemia
08/23
12/23
ChiCTR2000030998: Evaluation of efficacy and safety of Roxadustat in the treatment of anemia in patients with chronic kidney disease receiving hemodialysis or peritoneal dialysis: a real-world registration study in China

Not yet recruiting
4
200
 
Roxadustat
West China Hospital, Sichuan University; West China Hospital, Sichuan University, 1.3.5 project for disciplines of excellence, West China Hospital, Sichuan University
anemia in patients with chronic kidney disease receiving hemodialysis or peritoneal dialysis
 
 
NCT06115421: Effect of Low Doses of Hypoxia-inducible Factor- Prolyl Hydroxylase Enzyme Inhibitor Plus Iron in the Treatment of Anemia in Dialysis-dependent Chronic Kidney Disease Patients

Recruiting
4
72
RoW
Roxadustat, hypoxia-inducible factor- prolyl hydroxylase enzyme inhibitor
Alexandria University
Anemia in Dialysis-dependent CKD Patients
03/24
05/24
ChiCTR2100046322: A National, Multi-Center, Prospective Registry Study to Evaluate the Long-Term Safety and effectiveness of Roxadustat for Treatment of Anemia in Subjects with Chronic Kidney Disease (ROXSTAR Registry)

Completed
4
2000
 
Nil
The First Affiliated Hospital, Zhejiang University School of Medicine; FibroGen (China) Medical Technology Development Company Limited, FibroGen (China) Medical Technology Development Co., Ltd.
CKD anemia
 
 
Effectiveness and safety of roxadustat in Chinese patients with anemia of CKD receiving PD, ChiCTR2100044799: NANLING: An Open-Label Single Arm, Multicenter, Phase IV Study of the Effectiveness and Safety of Roxadustat in Chinese Patients with Anemia of ChronicKidney Disease (CKD) Receiving Peritoneal Dialysis (PD)

Completed
4
200
 
Roxadustat Treatment
Guangdong Provincial People's Hospital; Guangdong Provincial People's Hospital, FibroGen (China) Medical Technology Development Co., Ltd.
Renal Anemia
 
 
ChiCTR2100044135: a Multicentre real world study and pharmacoeconomic analysis of Roxadustat in the treatment of anemia in CKD

Recruiting
4
300
 
Roxadustat
Shenzhen People's Hospital; Level of the institution：, Shenzhen Key Laboratory of Kidney Diseases, Shenzhen People's Hospital
anemia in patients with chronic kidney disease receiving or not-receiving dialysis
 
 
ChiCTR2100045359: A Randomized, Control, Open-Label, Multi-center Study Evaluating the Efficacy and Safety of Roxadustat at Lower Starting Dose for the Treatment of Anemia in Subjects with Chronic Kidney Disease Not on Dialysis

Completed
4
250
 
1-step lower weight-based starting dose group: < 60 kg: 50 mg TIW, >= 60 kg: 70 mg TIW ;Control arm: standard weight-based starting dose group: < 60 kg: 70 mg TIW, >= 60 kg: 100 mg TIW
Chinese PLA General Hospital; Chinese PLA General Hospital, FibroGen (China) Medical Technology Development Company Limited
Chronic Kidney Disease
 
 
ChiCTR2300068533: Roxadustat for Anemia in Patients Receiving Maintenance Hemodialysis: A Single-center, Open-label, Randomized, Controlled Study

Recruiting
4
56
 
Roxadustat (Airuizhuo) ;Yibiao
Shanghai Ninth People’s Hospital, Shanghai Jiao Tong University School of Medicine; Shanghai Ninth People’s Hospital, Shanghai Jiao Tong University School of Medicine, self-financing
Anemia in CKD
 
 
ChiCTR2200061138: Efficacy and safety of roxadustat in delaying the progression of chronic kidney disease: a two-way, single center, cohort study

Not yet recruiting
4
66
 
Roxadustat capsule
Department of Nephrology, DaPing Hospital of Army Medical University, ChongQing, China; Department of Nephrology, DaPing Hospital of Army Medical University, Chongqing technological innovation and application demonstration (social and people's livelihood) general project
Chongqing technological innovation and application demonstration (social and people's livelihood) general project
 
 
ChiCTR2100047094: Effect of roxastat on anemia and vascular calcification in non-dialysis DKD patients with microinflammation

Recruiting
4
130
 
Roxadustat ;ESA
Pudong Hospital affiliated to Fudan University; Pudong Hospital affiliated to Fudan University, Research Fund
DKD
 
 
ChiCTR2300071087: Efficacy of Roxadustat on Anemia in CKD

Not yet recruiting
4
140
 
No ;No
The Second Affiliated Hospital of Shantou University Medical College; The Second Affiliated Hospital of Shantou University Medical College, N/A
chronic kidney disease
 
 
NCT06006949: Roxadustat Combined With Luspatercept Versus Luspatercept Monotherapy in the Treatment of Refractory MDS-RS

Not yet recruiting
4
62
RoW
Roxadustat, Luspatercept
Peking Union Medical College Hospital
Myelodysplastic Syndromes
08/24
08/25
REACH-ROAD, ChiCTR1900025765: Renal disEAse observational CoHort Database-ROxadustat in treating Anemia in Dialysis patients

Not yet recruiting
4
2000
 
N/A
Sichuan Provincial People's Hospital; Sichuan Provincial People's Hospital, self-funding
Chronic Kidney Disease
 
 
ChiCTR2100054190: Study of thyroid function status in patients with renal anemia before and after roxadustat or erythropoietin treatment

Recruiting
4
160
 
No ;No
Shenzhen Second People's Hospital, the First Affiliated Hospital of Shenzhen University; Shenzhen Second People's Hospital, the First Affiliated Hospital of Shenzhen University, None
Renal anemia and thryoid diseases
 
 
PANGU-stepup, NCT07045155: Pegmolesatide Treatment for Anemia in Patients Undergoing Long-term Dialysis

Not yet recruiting
4
240
RoW
The rHuEPO Monotherapy Group (Control Group), Control Group, The Pegmolesatide and Roxadustat Combination Therapy Group (Exploratory Group), Exploratory Group, The Pegmolesatide Monotherapy Group (Experimental group), Experimental group
Chinese PLA General Hospital, Jiangsu Hansoh Pharmaceutical Co., Ltd.
Dialysis; Complications, Chronic Kidney Disease 5D, Renal Anemia of Chronic Kidney Disease, Renal Anaemia, Renal Anemia, Chronic
12/27
12/28
ChiCTR2500100313: Evaluation of the efficacy of Roxadustat combined with oral iron in the treatment of renal anemia in hemodialysis patients who meet iron standards: a randomized controlled clinical study

Not yet recruiting
4
48
 
Roxadustat combined with oral iron supplements; Roxadustat
Ya'an People's Hospital; Ya'an People's Hospital, Project of Sichuan Geriatric Clinical Research Center
chronic kidney disease
 
 
NCT04925011: Investigating the Efficacy and Safety of Roxadustat (FG-4592) for Treatment of Anemia in Pediatric Patients With CKD

Recruiting
3
30
RoW
Roxadustat
Mao Jianhua
Anemia Associated With Chronic Kidney Disease
06/22
12/22
MATTERHORN, NCT03263091 / 2017-001773-17: Efficacy and Safety of Roxadustat for Treatment of Anemia in Participants With Lower Risk Myelodysplastic Syndrome With Low Red Blood Cell Transfusion Burden

Hourglass Jan 2023 - Dec 2023 : Data from trial for anemia in patients with MDS
Checkmark Data from trial for anemia in patients with MDS
Dec 2019 - Dec 2019: Data from trial for anemia in patients with MDS
Terminated
3
184
Europe, Canada, US, RoW
Roxadustat, FG-4592, ASP1517, AZD9941, Placebo
FibroGen, AstraZeneca, Astellas Pharma Inc
Primary MDS (Very Low, Low or Intermediate IPSS-R With <5% Blasts), Anemia
03/23
06/23
FGCL-4592-898, NCT05301517: A Study to Evaluate the Efficacy and Safety of Roxadustat for the Treatment of Anemia in Participants Receiving Chemotherapy Treatment for Non-Myeloid Malignancies

Completed
3
159
RoW
SEPO®, Recombinant human erythropoietin-α [rHuEPO-α], Roxadustat, FG-4592
FibroGen
Chemotherapy Induced Anemia
04/23
04/23
PRELIFS, NCT06772272: Effect of Perioperative Roxadustat in Elective Lumbar Interbody Fusion Surgery.

Active, not recruiting
3
158
RoW
Roxadustat, FG-4592, Evrenzo
Second Affiliated Hospital, School of Medicine, Zhejiang University
Perioperative Anemia
11/26
05/27
NCT05970172: A Study of Roxadustat to Treat Anemia in Children and Teenagers With Chronic Kidney Disease

Recruiting
3
100
Europe, RoW
Roxadustat, ASP1517, FG-4592, Evrenzo
Astellas Pharma Global Development, Inc.
Chronic Kidney Disease, Renal Anemia
11/25
09/26
NCT03303066: Efficacy and Safety of FG-4592 for Treatment of Anemia in Participants With Lower Risk Myelodysplastic Syndrome (MDS)

Hourglass Jan 2023 - Dec 2023 : Data from trial for anemia in patients with low risk MDS
Completed
2/3
43
RoW
FG-4592, Roxadustat, AZD9941, Placebo
FibroGen, AstraZeneca
Anemia, Myelodysplastic Syndrome
01/23
02/23
ACTRN12625000491460: A study of the short-term effects of oral Roxadustat in volunteers over the age of 40.

Not yet recruiting
2
10
 
Royal Perth Hospital, National Health and Medical Research Council
Postoperative Complications, Surgical Site Infection
 
 
ACTRN12624000188538: A pilot study of preoperative Roxadustat in patients undergoing major surgery.

Recruiting
2
150
 
Royal Perth Hospital, National Health and Medical Research Council
Postoperative Complications, Surgical site infection
 
 
ROXAMI, NCT04803864: Study of Roxadustat in the Treatment of Acute Myocardial Infarction

Recruiting
2
158
RoW
Roxadustat, Evrenzo
Ruijin Hospital
ST Elevation Myocardial Infarction
09/22
08/23
NCT05010460: Study of Roxadustat for Reducing the Incidence of Acute Kidney Injury After Coronary Artery Bypass Grafting

Recruiting
2
318
RoW
Roxadustat, Evrenzo, Placebo
Peking Union Medical College Hospital, Beijing Hospital
Coronary Artery Bypass
08/23
10/23
FOXTROT, NCT05810311: The Effect of Roxadustat on Renal Oxygenation in Diabetes Nephropathy

Not yet recruiting
2
30
Europe
Roxadustat, Evrenzo, Darbepoietin Alfa, Aranesp
Region Stockholm
Diabetes Complications, Diabetes; Nephropathy (Manifestation)
01/27
12/27
ROXA-HD-MIA, NCT06903559: Roxadustat's Effect on Heart, Nutrition, and Inflammation in Hemodialysis Patients

Recruiting
1/2
46
RoW
Roxadustat, Evernzo, Conventional Anemia Management, Erythropoiesis-Stimulating Agent, Iron Supplementation
Mansoura University
Kidney Failure, Chronic, Malnutrition-Inflammation Syndrome, Anemia in End Stage Renal Disease, Cardiovascular Diseases (CVD)
10/25
11/25
ROXA-BN-HD, NCT06917950: Roxadustat for Bone and Neuropsychiatric Aspects in Hemodialysis Patients

Recruiting
1/2
46
RoW
Roxadustat, Conventional Anemia Management
Mansoura University
Kidney Failure,Chronic, Anemia in End Stage Renal Disease, Depression Anxiety Disorder
10/25
11/25
NCT06020833: A Single-arm Trial of Roxadustat Combined With Retinoic Acid in the Treatment of Refractory Low-risk MDS

Not yet recruiting
1/2
25
NA
Roxadustat in combination with retinoic acid
Peking Union Medical College Hospital
Myelodysplastic Syndromes
10/25
12/26
HEC53856-RAD-102, NCT04925661: HEC53856 Phase Ib Study in Patients With Non-dialysis Renal Anemia

Completed
1
40
RoW
HEC53856, Roxadustat, Placebo
Sunshine Lake Pharma Co., Ltd., Nicoya Therapeutics (Shanghai) Co., Ltd.
Chronic Kidney Diseases, Renal Anemia
08/23
08/23
ChiCTR2200058594: A randomized controlled study of Rosallistat in the treatment of anemia in patients with multiple myeloma renal insufficiency

Recruiting
1
86
 
Roxadustat ;None
The First Affiliated Hospital of Zhejiang University School of Medicine; The First Affiliated Hospital of Zhejiang University School of Medicine, none
Multiple Myeloma
 
 
ChiCTR2000039194: Clinical application of hypoxia inducible factor proline hydroxylase inhibitor in restless legs syndrome of end stage renal disease

Recruiting
N/A
240
 
Roxadustat ;Oral neurotropin ;Neurotropin injection ;HDF
The Sencond Hospital of Tianjin medical university; The Sencond Hospital of Tianjin medical university, Self financing
restless legs syndrome
 
 
ChiCTR2100048276: Safety assessment of roxadustat in the treatment of renal anemia in dialysis patients: a retrospective study based on the ''Ruixiang Xinsheng'' patient assistance program

Not yet recruiting
N/A
8000
 
Null
Beijing University First Hospital; Beijing University First Hospital, FibroGen (China) Medical Technology Development Co., Ltd.
Renal Anemia
 
 
ChiCTR2100044086: Effect of Roxadustat on Erythrocyte Life Span in Long-term Hemodialysis Patients with Renal Anemia

Completed
N/A
27
 
Roxadustat
Shandong Provincial Hospital; Shandong Provincial Hospital, Special Fund for Renal Anemia
Maintenance Hemodialysis with Renal Anemia
 
 
ChiCTR2000031222: Cancelled by the investigator A prospective randomized controlled trial of roxadustat for the first recipient to alleviate delayed graft function and acute rejection after renal transplantation

Suspended
N/A
238
 
Roxadustat Capsules and routine treatment ;routine treatment
The Third Affiliated Hospital of Sun Yat-Sen University; The Third Affiliated Hospital, Sun Yat-Sen University, Researchers spontaneous
Delayed graft function after renal transplantation
 
 
NCT05053893: Roxadustat Combined With Sacubitril Valsartan Sodium Tablets in the Treatment of Cardiorenal Anemia Syndrome

Recruiting
N/A
40
RoW
Roxadustat;Sacubitril Valsartan Sodium Tablets;, Entresto®, EPO; ACEI / ARB
The Affiliated Hospital of Qingdao University
Cardio-Renal Syndrome
07/22
09/22
ChiCTR2000036633: The effect of roxadustat on infarct size reduction of acute myocardial infarction: a randomized controlled trial

Not yet recruiting
N/A
158
 
Roxadustat 100mg, three times a week, for 2 weeks; Standard treatment. ;Standard treatment
Ruijin Hospital affiliated to Shanghai Jiaotong University School of Medicine; Ruijin Hospital affiliated to Shanghai Jiaotong University School of Medicine, Shanghai shenkang hospital development center
Acute Myocardial Infarction
 
 
ChiCTR2100048566: Effect of oral roxadustat on renal anemia after allogeneic kidney transplantation: an observational study

Not yet recruiting
N/A
152
 
None
Renji Hospital affiliated to Shanghai Jiao Tong University Medical College; Renji Hospital affiliated to Shanghai Jiao Tong University Medical College, None
Kidney transplant
 
 
ChiCTR2200065159: Efficacy of roxadustat in patients with renal anemia associated with inflammatory status

Recruiting
N/A
100
 
None
Zhongda Hospital Affiliated to Southeast University; Zhongda Hospital Affiliated to Southeast University, Self financing
Renal anemia
 
 
ChiCTR2100050031: A practical randomized controlled trial of hypoxia inducible factor prolyl hydroxylase inhibitor in the treatment of cardio-renal-anemia syndrome

Not yet recruiting
N/A
60
 
Roxadustat capsule ;recombinant human erythropoietin
Beijing Hepingli Hospital; Beijing Hepingli Hospital, Dongcheng District Health Technology Program
cardio-renal-anemia syndrome
 
 
NCT04502537: Roxadustat for Anemia in Patients With CKD

Recruiting
N/A
200
RoW
Roxadustat, Roxadustat capsules, erythropoietin, Recombinant Human Erythropoietin Injection(CHO cell)
Shenzhen Second People's Hospital
Anemia of Chronic Kidney Disease
06/23
09/23
ChiCTR2300076409: Effect of roxadustat in peritoneal dialysis patients with erythropoietin hyporesponsiveness: A real-world 16-week study

Completed
N/A
152
 
N/A; N/A
The Second Affiliated Hospital of Xuzhou Medical University; The Second Affiliated Hospital of Xuzhou Medical University, Self-financed
Peritoneal dialysis
 
 
ChiCTR2400086902: Efficacy of roxadustat versus ESAs in peritoneal dialysis patients during the COVID-19 pandemic: A retrospective study

Completed
N/A
154
 
N/A; N/A
The Second Affiliated Hospital of Xuzhou Medical University; The Second Affiliated Hospital of Xuzhou Medical University, Self-financing
Peritoneal dialysis
 
 
ChiCTR2200065296: A multicenter clinical study of roxadustat to improve outcomes in peritoneal dialysis patients

Not yet recruiting
N/A
100
 
none
Shanghai East hospital (East Hospital Affiliated to Tongji University); Shanghai East Hospital (East Hospital Affiliated to Tongji University), Shanghai East Hospital,
end stage renal disease
 
 
ChiCTR2300070478: Clinical cohort study of the effect of hypoxia-inducible factor prolyl hydroxylase inhibitor (roxadustat) on cognitive function in maintenance hemodialysis patients

Recruiting
N/A
100
 
NA ;NA
Deyang People's Hospital; Deyang People's Hospital, Self-funded
Chronic kidney disease
 
 
ChiCTR2200057485: The study of efficacy and safety of Roxadustat in anemia patients after kidney transplantation

Not yet recruiting
N/A
160
 
Roxadustat ;Recombinant human erythropoietin
West China Hospital, Sichuan University; West China Hospital, Sichuan University, Supported by 1.3.5 Project No.ZYJC18004
kindey transplant
 
 
ChiCTR2500097135: Effect of Roxadustat treatment on patients with diabetes mellitus combined with chronic kidney disease

Not yet recruiting
N/A
500
 
NA; NA; NA
Shanghai General Hospital; Shanghai General Hospital, Self selected topic
non dialysis type 2 diabetes patients with chronic kidney disease
 
 
NCT04408820: Post-marketing Surveillance of EVRENZO® Tablets (Roxadustat) in Patients With Renal Anemia

Active, not recruiting
N/A
2104
Japan
Roxadustat, ASP1517, Evrenzo
Astellas Pharma Inc
Renal Anemia
06/25
06/25
ChiCTR2500096786: An Observational Study on the Increased Synthesis of Fetal Hemoglobin Induced by Roxadustat in Patients with Renal Anemia

Recruiting
N/A
100
 
None; None
Army Military Medical University Second Affiliated Hospital; Army Military Medical University Second Affiliated Hospital, Chongqing Municipal Education Commission Science and Technology Research Program Major Project, KJZD-M202312802, Study on the Role and Mechanism of Heterogeneity of Hematopoietic Stem Cell Function in the Efficacy of Hematopoietic Stem Cell Transplantation
Chronic kidney disease
 
 
Roxa-NDD-CKD Anemia Study, ChiCTR2500097406: A multicenter, prospective study on the efficacy and safety of roxadustat (Bereisheng®) in the treatment of renal anemia in non-dialysis patients with chronic kidney disease

Not yet recruiting
N/A
50
 
Roxadustat Capsules
The First Affiliated Hospital of Jinan University; Chengdu Brilliant Pharmaceutical Co., Ltd., Chengdu Brilliant Pharmaceutical Co., Ltd.
Renal anemia in non-dialysis patients with chronic kidney disease
 
 
ChiCTR2200061848: A single-center prospective observational cohort study on the effect of different therapeutic strategies on cardiovascular prognosis of patients with end-stage renal disease complicated with renal anemia

Not yet recruiting
N/A
360
 
Erythropoietin ;Roxadustat ;Roxadustat
The Second Hospital of Tianjin Medical University; The Second Hospital of Tianjin Medical University, self-raised
Chronic Kidney Disease
 
 
FG-3246 / Fortis Therap, FibroGen
NCT06842498: A Study of FG-3246 in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Not yet recruiting
2
75
US
FG-3246, FOR46
FibroGen
Metastatic Castration-Resistant Prostate Cancer
09/27
09/27
NCT05011188: FOR46 in Combination With Enzalutamide in Patients With Metastatic Castration Resistant Prostate Cancer

Recruiting
1/2
41
US
FOR46, Antibody-Drug Conjugate (ADC), anti-CD46 antibody conjugate, Enzalutamide, XTANDI, Pegfilgrastim, G-CSF, Blood Samples, Blood Specimen, Biospecimen
Rahul Aggarwal, Fortis Therapeutics, Inc., FibroGen
Metastatic Castration-resistant Prostate Cancer, Prostate Cancer
04/27
04/27
NCT03575819: A Phase 1 Study of FOR46 in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Completed
1
56
US
FOR46
Fortis Therapeutics, Inc.
Prostate Cancer Metastatic
11/23
11/23
FG-3165 / FibroGen
No trials found
HFB200901 / HiFiBiO, FibroGen
No trials found
HFB101110 / FibroGen
No trials found

Download Options